ZHOU Sai1,MA Hongli2*,RUAN Wenzhen1. Management Model for Intravenous Medication Safety Developed Based on Informatization[J]. Chinese General Practice, 2020, 23(24): 3064-3069. DOI: 10.12114/j.issn.1007-9572.2020.00.207.
周赛1,马红丽2*,阮文珍1. 基于信息化构建的静脉安全用药管理模式的应用研究[J]. 中国全科医学, 2020, 23(24): 3064-3069. DOI: 10.12114/j.issn.1007-9572.2020.00.207.
[1]刘震,姚静亚,陶霞,等.我院2013年住院病区医嘱审核情况分析[J].中国药房,2015,26(5):599-601.
LIU Z,YAO J Y,TAO X,et al.Analysis of inpatient medical orders review in our hospital in 2013[J].China Pharmacy,2015,26(5):599-601.
[2]夏志丹,肖晓林,吴一凡.医院用药错误和接近失误分析与改进成效评价[J].中国药业,2017,26(17):84-86.DOI:10.3969/j.issn.1006-4931.2017.17.029.
XIA Z D,XIAO X L,WU Y F.Effectiveness evaluation of improvement of medication errors and nearmiss in a hospital[J].China Pharmaceuticals,2017,26(17):84-86.DOI:10.3969/j.issn.1006-4931.2017.17.029.
[3]World Health Organization.WHO launches global effort to halve medication-related errors in 5 years[EB/OL].(2017-03-29)[2018-08-24].https://www.who.int/news-room/detail/29-03-2017-who-launches-global-effort-to-halve-medication-related-errors-in-5-years.
[4]黄夏薇,黄丽华.临床用药错误原因及预防的研究进展[J].护理与康复,2015,14(1):20-23.DOI:10.3969/j.issn.1671-9875.2015.01.006.
[5]林兰,黄梅英,林艳萍.规范药品说明书管理与学习对ICU护士安全用药的影响[J].临床合理用药杂志,2019,12(5):164-165.DOI:10.15887/j.cnki.13-1389/r.2019.05.109.
[6]MANIAS E,WILLIAMS A,LIEW D.Interventions to reduce medication errors in adult intensive care:a systematic review[J].Br J Clin Pharmacol,2012,74(3):411-423.DOI:10.1111/j.1365-2125.2012.04220.x.
[7]王倾,李海婷,李辉辉,等.智慧化静脉给药护理信息系统的设计[J].中国数字医学,2017,12(2):105-106,108.DOI:10.3969/j.issn.1673-7571.2017.2.037.
[10]AIKAWA N,ISHIZAKA A,HIRASAWA H,et al.Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor,Sivelestat,for the treatment of acute lung injury associated with systemic inflammatory response syndrome:a phase Ⅳstudy[J].Pulm Pharmacol Ther,2011,24(5):549-554.DOI:10.1016/j.pupt.2011.03.001.
[11]LIANG B A.FDA use of the black box warning:time for reevaluation as a safety tool[J].J Clin Anesth,2002,14(8):561-563.DOI:10.1016/s0952-8180(02)00444-0.
[12]邱瑞瑾,李敏,胡嘉元,等.中成药上市后临床安全性评价核心数据集的构建方法探索[J].世界科学技术-中医药现代化,2018,20(10):1723-1728.
QIU R J,LI M,HU J Y,et al.Exploration of the method of developing core data sets for post-marketing clinical safety evaluation of Chinese proprietary medicine[J].Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology,2018,20(10):1723-1728.
[13]许思华.痰热清注射液的不良反应分析[J].北方药学,2017,14(2):151-152.
XU S H.Analysis of the adverse effects of Tanreqing Injection[J].Journal of North Pharmacy,2017,14(2):151-152.
[14]张云玲,阚晓宏,贺思勋,等.383例参麦注射液医院集中监测临床应用分析[J].安徽医药,2018,22(3):526-529.DOI:10.3969/j.issn.1009-6469.2018.03.035.
ZHANG Y L,KAN X H,HE S X,et al.Clinical application of hospital centralized monitoring on 383 cases using Shenmai injection[J].Anhui Medical and Pharmaceutical Journal,2018,22(3):526-529.DOI:10.3969/j.issn.1009-6469.2018.03.035.
[15]范华,何杰文.我院86例痰热清注射剂不良反应回顾性分析[J].海峡药学,2017,29(7):270-271.
[16]徐文俊,许建国,朱华,等.雷贝拉唑或奥美拉唑联合莫沙必利治疗反流性食管炎有效性和安全性的meta分析[J].药学与临床研究,2017,25(2):145-148.DOI:10.13664/j.cnki.pcr.2017.02.015.
XU W J,XU J G,ZHU H,et al.Efficacy and safety of rabeprazole versus omeprazole plus mosapride for reflux esophagitis:a meta-analysis[J].Pharmaceutical and Clinical Research,2017,25(2):145-148.DOI:10.13664/j.cnki.pcr.2017.02.015.
[17]KUSANO M,KATO M,FUJISHIRO M,et al.The efficacy and safety of rabeprazole 10Mg twice daily in maintenance therapy for reflux esophagitis patients refractory to standard once daily administration of PPI:the Japan-based extend study[J].Gastroenterology,2017,152(5):S460.DOI:10.1016/S0016-5085(17)31736-5.
[18]KINOSHITA Y,KUSANO M,IWAKIRI K,et al.Efficacy and safety profile of Z-215 (azeloprazole sodium),a proton pump inhibitor,compared with rabeprazole sodium in patients with reflux esophagitis:a phaseⅡ,multicenter,randomized,double-blind,comparative study[J].Curr Ther Res Clin Exp,2018,88:26-34.DOI:10.1016/j.curtheres.2018.03.004.
[19]KINOSHITA Y,KATO M,FUJISHIRO M,et al.Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor:the Japan-based extend study[J].J Gastroenterol,2018,53(7):834-844.DOI:10.1007/s00535-017-1417-z.
[20]乐阳.雷贝拉唑与奥美拉唑治疗幽门螺杆菌相关性消化性溃疡的疗效比较[J].基层医学论坛,2018,22(16):2305-2306.DOI:10.19435/j.1672-1721.2018.16.101.
[21]黄盖,田邦妮,陈五一.雷贝拉唑与奥美拉唑三联七日用药方案治疗幽门螺杆菌相关性消化性溃疡的比较研究[J].现代中西医结合杂志,2015,24(5):495-497.DOI:10.3969/j.issn.1008-8849.2015.05.015.
[22]李冰.反流性食管炎应用雷贝拉唑联合莫沙必利方案治疗效果及价值分析[J].中外医疗,2018,37(5):138-140.DOI:10.16662/j.cnki.1674-0742.2018.05.138.
LI B.Effect and value analysis of rabeprazole combined with mosapride on re-flux esophagitis[J].China Foreign Medical Treatment,2018,37(5):138-140.DOI:10.16662/j.cnki.1674-0742.2018.05.138.
WANG Q,LI H T,LI H H,et al.Design of the intelligent intravenous administration nursing information system[J].China Digital Medicine,2017,12(2):105-106,108.DOI:10.3969/j.issn.1673-7571.2017.2.037.
[8]邸禄芹,丁俊琴,张秀果,等.前馈控制在预防静脉给药错误的效果观察[J].护士进修杂志,2016,31(20):1852-1855.DOI:10.16821/j.cnki.hsjx.2016.20.010.
DI L Q,DING J Q,ZHANG X G,et al.Observation on the effect of feed-forward control for preventing intravenous drug administration error[J].Journal of Nurses Training,2016,31(20):1852-1855.DOI:10.16821/j.cnki.hsjx.2016.20.010.
[9]陈江霞,马红丽,朱美丽.基于信息化技术的输液安全控制系统的应用[J].护士进修杂志,2019,34(2):136-139.DOI:10.16821/j.cnki.hsjx.2019.02.010.
[10]陆秀文,徐红,楼建华.128起给药错误分析[J].中国护理管理,2011,11(2):63-66.DOI:10.3969/j.issn.1672-1756.2011.02.021.
LU X W,XU H,LOU J H.Analysis of 128 medication errors[J].Chinese Nursing Management,2011,11(2):63-66.DOI:10.3969/j.issn.1672-1756.2011.02.021.